The RNA-binding protein RBM47 is a novel regulator of cell fate decisions by transcriptionally controlling the p53-p21-axis.
Journal
Cell death and differentiation
ISSN: 1476-5403
Titre abrégé: Cell Death Differ
Pays: England
ID NLM: 9437445
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
17
10
2018
accepted:
28
08
2019
revised:
26
08
2019
pubmed:
13
9
2019
medline:
30
6
2021
entrez:
13
9
2019
Statut:
ppublish
Résumé
In recent years it has become more and more apparent that the regulation of gene expression by RNA-binding proteins (RBPs) is of utmost importance for most cellular signaling pathways. RBPs control several aspects of RNA biogenesis including splicing, localization, stability, and translation efficiency. One of these RBPs is RBM47 that recently has been suggested to function as a tumor suppressor as it was shown to suppress breast and colon cancer progression. Here we demonstrate that RBM47 is an important regulator of basal and DNA damage-induced p53 and p21
Identifiants
pubmed: 31511650
doi: 10.1038/s41418-019-0414-6
pii: 10.1038/s41418-019-0414-6
pmc: PMC7206044
doi:
Substances chimiques
Cyclin-Dependent Kinase Inhibitor p21
0
RBM47 protein, human
0
RNA-Binding Proteins
0
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1274-1285Références
Kastenhuber ER, Lowe SW. Putting p53 in context. Cell. 2017;170:1062–78.
doi: 10.1016/j.cell.2017.08.028
Marcel V, Catez F, Diaz JJ. p53, a translational regulator: contribution to its tumour-suppressor activity. Oncogene. 2015;34:5513–23.
doi: 10.1038/onc.2015.25
Zaccara S, Tebaldi T, Pederiva C, Ciribilli Y, Bisio A, Inga A. p53-directed translational control can shape and expand the universe of p53 target genes. Cell Death Differ. 2014;21:1522–34.
doi: 10.1038/cdd.2014.79
Reinhardt HC, Cannell IG, Morandell S, Yaffe MB. Is post-transcriptional stabilization, splicing and translation of selective mRNAs a key to the DNA damage response? Cell Cycle. 2011;10:23–7.
doi: 10.4161/cc.10.1.14351
Sohn D, Peters D, Piekorz RP, Budach W, Jänicke RU. miR-30e controls DNA damage-induced stress responses by modulating expression of the CDK inhibitor p21WAF1/CIP1 and caspase-3. Oncotarget. 2016;7:15915–29.
pubmed: 26895377
pmcid: 4941286
Zhang J, Chen X. Posttranscriptional regulation of p53 and its targets by RNA-binding proteins. Curr Mol Med. 2008;8:845–9.
doi: 10.2174/156652408786733748
Pereira B, Billaud M, Almeida R. RNA-binding proteins in cancer: old players and new actors. Trends Cancer. 2017;3:506–28.
doi: 10.1016/j.trecan.2017.05.003
Wurth L, Gebauer F. RNA-binding proteins, multifaceted translational regulators in cancer. Biochim Biophys Acta. 2015;1849:881–6.
doi: 10.1016/j.bbagrm.2014.10.001
Guan R, El-Rass S, Spillane D, Lam S, Wang Y, Wu J, et al. rbm47, a novel RNA binding protein, regulates zebrafish head development. Dev Dyn. 2013;242:1395–404.
doi: 10.1002/dvdy.24039
Fossat N, Radziewic T, Jones V, Tourle K, Tam PP. Conditional restoration and inactivation of Rbm47 reveal its tissue-context requirement for viability and growth. Genesis. 2016;54:115–22.
doi: 10.1002/dvg.22920
Cieply B, Park JW, Nakauka-Ddamba A, Bebee TW, Guo Y, Shang X, et al. Multiphasic and dynamic changes in alternative splicing during induction of pluripotency are coordinated by numerous RNA-binding proteins. Cell Rep. 2016;15:247–55.
doi: 10.1016/j.celrep.2016.03.025
Vanharanta S, Marney CB, Shu W, Valiente M, Zou Y, Mele A, et al. Loss of the multifunctional RNA-binding protein RBM47 as a source of selectable metastatic traits in breast cancer. Elife. 2014;3:e02734.
Treiber T, Treiber N, Plessmann U, Harlander S, Daiss JL, Eichner N, et al. A compendium of RNA-binding proteins that regulate microRNA biogenesis. Mol Cell. 2017;66:270–84 e13.
doi: 10.1016/j.molcel.2017.03.014
Fossat N, Tourle K, Radziewic T, Barratt K, Liebhold D, Studdert JB, et al. C to U RNA editing mediated by APOBEC1 requires RNA-binding protein RBM47. EMBO Rep. 2014;15:903–10.
doi: 10.15252/embr.201438450
Wei Y, Zhang F, Zhang Y, Wang X, Xing C, Guo J, et al. Post-transcriptional regulator Rbm47 elevates IL-10 production and promotes the immunosuppression of B cells. Cell Mol Immunol. 2019;16:580–9.
Sakurai T, Isogaya K, Sakai S, Morikawa M, Morishita Y, Ehata S, et al. RNA-binding motif protein 47 inhibits Nrf2 activity to suppress tumor growth in lung adenocarcinoma. Oncogene. 2016;35:5000–9.
doi: 10.1038/onc.2016.35
Rokavec M, Kaller M, Horst D, Hermeking H. Pan-cancer EMT-signature identifies RBM47 down-regulation during colorectal cancer progression. Sci Rep. 2017;7:4687.
doi: 10.1038/s41598-017-04234-2
Puisieux A, Brabletz T, Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol. 2014;16:488–94.
doi: 10.1038/ncb2976
Hein MY, Hubner NC, Poser I, Cox J, Nagaraj N, Toyoda Y, et al. A human interactome in three quantitative dimensions organized by stoichiometries and abundances. Cell. 2015;163:712–23.
doi: 10.1016/j.cell.2015.09.053
Dutertre M, Lambert S, Carreira A, Amor-Gueret M, Vagner S. DNA damage: RNA-binding proteins protect from near and far. Trends Biochem Sci. 2014;39:141–9.
doi: 10.1016/j.tibs.2014.01.003
Peters D, Radine C, Reese A, Budach W, Sohn D, Jänicke RU. TheDEAD-box RNA helicase DDX41 is a novel repressor of p21(WAF1/CIP1) mRNA translation. J Biol Chem. 2017;292:8331–41.
doi: 10.1074/jbc.M116.772327
Sohn D, Budach W, Jänicke RU. Caspase-2 is required for DNA damage-induced expression of the CDK inhibitor p21(WAF1/CIP1). Cell Death Differ. 2011;18:1664–74.
doi: 10.1038/cdd.2011.34
Jänicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem. 1998;273:9357–60.
doi: 10.1074/jbc.273.16.9357
Brenner JC, Graham MP, Kumar B, Saunders LM, Kupfer R, Lyons RH, et al. Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck. 2010;32:417–26.
pubmed: 19760794
pmcid: 3292176
Drewinko B, Romsdahl MM, Yang LY, Ahearn MJ, Trujillo JM. Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line. Cancer Res. 1976;36(2 Pt 1):467–75.
pubmed: 1260746
Wang S, El-Deiry WS. p73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints. Cancer Res. 2006;66:6982–9.
doi: 10.1158/0008-5472.CAN-06-0511
Graupner V, Schulze-Osthoff K, Essmann F, Jänicke RU. Functional characterization of p53beta and p53gamma, two isoforms of the tumor suppressor p53. Cell Cycle. 2009;8:1238–48.
doi: 10.4161/cc.8.8.8251
Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O. Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc. 2009;4:1798–806.
doi: 10.1038/nprot.2009.191
Roberts TC, Hart JR, Kaikkonen MU, Weinberg MS, Vogt PK, Morris KV. Quantification of nascent transcription by bromouridine immunocapture nuclear run-on RT-qPCR. Nat Protoc. 2015;10:1198–211.
doi: 10.1038/nprot.2015.076
Meek DW, Anderson CW. Posttranslational modification ofp53: cooperative integrators of function. Cold Spring Harb Perspect Biol. 2009;1:a000950.
doi: 10.1101/cshperspect.a000950
Karni-Schmidt O, Lokshin M, Prives C. The roles of MDM2 and MDMX in cancer. Annu Rev Pathol. 2016;11:617–44.
doi: 10.1146/annurev-pathol-012414-040349
Sohn D, Essmann F, Schulze-Osthoff K, Jänicke RU. p21 blocks irradiation-induced apoptosis downstream of mitochondria by inhibition of cyclin-dependent kinase-mediated caspase-9 activation. Cancer Res. 2006;66:11254–62.
doi: 10.1158/0008-5472.CAN-06-1569
Jänicke RU, Sohn D, Essmann F, Schulze-Osthoff K. The multiple battles fought by anti-apoptotic p21. Cell Cycle. 2007;6:407–13.
doi: 10.4161/cc.6.4.3855
Saldana-Meyer R, Recillas-Targa F. Transcriptional and epigenetic regulation of the p53 tumor suppressor gene. Epigenetics. 2011;6:1068–77.
doi: 10.4161/epi.6.9.16683
Baillat D, Laitem C, Leprivier G, Margerin C, Aumercier M. Ets-1 binds cooperatively to the palindromic Ets-binding sites in the p53 promoter. Biochem Biophys Res Commun. 2009;378:213–7.
doi: 10.1016/j.bbrc.2008.11.035
Suzuki H, Romano-Spica V, Papas TS, Bhat NK. ETS1 suppresses tumorigenicity of human colon cancer cells. Proc Natl Acad Sci USA. 1995;92:4442–6.
doi: 10.1073/pnas.92.10.4442
Ray D, Kazan H, Cook KB, Weirauch MT, Najafabadi HS, Li X, et al. A compendium of RNA-binding motifs for decoding gene regulation. Nature. 2013;499:172–7.
doi: 10.1038/nature12311
Chaudhary R, Lal A. Long noncoding RNAs in the p53 network. Wiley Interdiscip Rev RNA. 2017;8:e1410.
Tano K, Onoguchi-Mizutani R, Yeasmin F, Uchiumi F, Suzuki Y, Yada T, et al. Identification of minimal p53 promoter region regulated by MALAT1 in human lung adenocarcinoma cells. Front Genet. 2017;8:208.
doi: 10.3389/fgene.2017.00208
Zhai N, Xia Y, Yin R, Liu J, Gao F. A negative regulation loop of long noncoding RNA HOTAIR and p53 in non-small-cell lung cancer. Onco Targets Ther. 2016;9:5713–20.
doi: 10.2147/OTT.S110219
Jänicke RU, Sohn D, Schulze-Osthoff K. The dark side of a tumor suppressor: anti-apoptotic p53. Cell Death Differ. 2008;15:959–76.
doi: 10.1038/cdd.2008.33
Pappas K, Xu J, Zairis S, Resnick-Silverman L, Abate F, Steinbach N, et al. p53 maintains baseline expression of multiple tumor suppressor genes. Mol Cancer Res. 2017;15:1051–62.
doi: 10.1158/1541-7786.MCR-17-0089
Kim YE, Won M, Lee SG, Park C, Song CH, Kim KK. RBM47-regulated alternative splicing of TJP1 promotes actin stress fiber assembly during epithelial-to-mesenchymal transition. Oncogene. 2019. https://doi.org/10.1038/s41388-019-0892-5 . [Epub ahead of print].
Rojo de la Vega M, Chapman E, Zhang DD. NRF2 and the hallmarks of cancer. Cancer Cell. 2018;34:21–43.
doi: 10.1016/j.ccell.2018.03.022